11 completed, 4 terminated. 9 Phase 3, 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 7, Terminated 2 |
| Phase 2 | 4 | Completed 2, Terminated 2 |
| Phase 1 | 2 | Completed 2 |
Follow Sol-Gel Technologies, Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib - Gorlin Syndrome | Phase 3 | Completed | Sol-Gel Technologies, Ltd. | 113 | 2024-03-17 | 2026-09-18 |
| Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties Encapsulated Benzoyl Peroxide Cream - Papulopustular Rosacea | Phase 1 | Completed | Sol-Gel Technologies, Ltd. | 31 | 2020-06-10 | 2023-04-18 |
| Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome) Patidegib Topical Gel, 2% - Basal Cell Nevus Syndrome | Phase 3 | Terminated | Sol-Gel Technologies, Ltd. | 108 | 2020-06-03 | 2024-09-24 |
| A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle - Recurrent Basal Cell Carcinoma | Phase 2 | Terminated | Sol-Gel Technologies, Ltd. | 50 | 2019-12-20 | 2026-07-21 |
| MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 S6G5T-3, Retin-A® 0.1% Cream - Acne Vulgaris | Phase 1 | Completed | Sol-Gel Technologies, Ltd. | 62 | 2019-06-27 | 2020-03-18 |
| Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome) Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle - Basal Cell Nevus Syndrome | Phase 3 | Completed | Sol-Gel Technologies, Ltd. | 174 | 2019-02-19 | 2024-07-03 |
| A Study of S6G5T-3 in the Treatment of Acne Vulgaris S6G5T-3, S6G5T-8 - Acne Vulgaris | Phase 3 | Completed | Sol-Gel Technologies, Ltd. | 424 | 2018-12-21 | 2021-12-16 |
| Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream 5-FU Cream, Efudex®, Vehicle - Actinic Keratosis (AK) | Phase 3 | Completed | Sol-Gel Technologies, Ltd. | 462 | 2018-12-21 | 2020-03-18 |
| A Study of S6G5T3 in the Treatment of Acne Vulgaris S6G5T-3, S6G5T-8 - Acne Vulgaris | Phase 3 | Completed | Sol-Gel Technologies, Ltd. | 434 | 2018-12-14 | 2021-12-16 |
| A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea S5G4T-1 - Papulopustular Rosacea | Phase 3 | Terminated | Sol-Gel Technologies, Ltd. | 547 | 2018-09-12 | 2021-12-15 |
| A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea S5G4T-1, S5G4T-2 - Papulopustular Rosacea | Phase 3 | Completed | Sol-Gel Technologies, Ltd. | 372 | 2018-06-21 | 2021-12-15 |
| A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea S5G4T-1, S5G4T-2 - Papulopustular Rosacea | Phase 3 | Completed | Sol-Gel Technologies, Ltd. | 361 | 2018-06-18 | 2021-12-14 |
| Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis S2G6T-1, S2G6T-2, S2G6T-3 - Tinea Pedis | Phase 2 | Terminated | Sol-Gel Technologies, Ltd. | 283 | 2016-09-01 | 2020-11-18 |
| Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris S6G5T-3, S6G5T-1, S6G5T-5 - Acne Vulgaris | Phase 2 | Completed | Sol-Gel Technologies, Ltd. | 726 | 2016-05-01 | 2019-09-19 |
| A Study of DER 45-EV Gel to Treat Rosacea DER 45 EV, Vehicle - Rosacea | Phase 2 | Completed | Sol-Gel Technologies, Ltd. | 92 | 2012-01-01 | 2015-01-09 |
Rosacea (5) · Acne Vulgaris (4) · Basal Cell Nevus Syndrome (4) · Carcinoma, Basal Cell (3) · Keratosis, Actinic (1) · Rombo syndrome (1) · Syndrome (1) · Tinea Pedis (1) · Xeroderma Pigmentosum (1)
Fluorouracil (1) · IPI-926 (1) · Tretinoin (1)
United States (15) · France (3) · Germany (3) · Italy (3) · Netherlands (3) · Spain (3) · United Kingdom (3) · Belgium (2) · Denmark (2) · Canada (1)
Kathleen O Ashenfelter, MS (1) · Ofra Levy-Hacham, PhD (1) · Piyush Sheladia, M.S. (1)
PMID 37636253, PMID 37636251, PMID 39148964
2023 (1)